Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCT2080222415
JPRN-jRCT2080222415
Unknown
Phase 2

A Phase II Study to Assess the Safety and Immunogenicity of subcutaneous DNK-FLU in Healthy Japanese Adults

DENKA SEIKEN CO.,LTD.0 sites50 target enrollmentMarch 5, 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
DENKA SEIKEN CO.,LTD.
Enrollment
50
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 5, 2014
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Healthy Adults

Exclusion Criteria

  • •Known history of influenza or received influenza vaccination within six months.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A phase I study to evaluate safety and immunogenicity of recombinant protein candidate vaccine against SARS-CoV-2 in healthy volunteers.SARS-CoV-2MedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2021-001411-82-ESABORATORIOS HIPRA, S.A.30
Recruiting
Not Applicable
TaMoVaC II
PACTR201211000435126Swedish Institute for Infectious Disease Control198
Active, not recruiting
Phase 1
Study to determine the safety and immunogenicity of COVID-eVax, a vaccine for COVID-19 in healthy adult volunteers.COVID-19 prevention.MedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2020-003734-20-ITTakis S.r.l.160
Active, not recruiting
Phase 1
A Phase I/II study to assess the safety and immunogenicity of recMAGE-A3+AS15 cancer immunotherapeutic given as adjuvant therapy, with or without adjuvant chemo(-radio)therapy, to patients with MAGE-A3-positive Non-Small Cell Lung cancer (stage IB, II or III) - MAGE3-AS15-NSC-001on-Small Cell Lung CancerMedDRA version: 6.1Level: PTClassification code 10061873
EUCTR2006-004777-10-ITGlaxoSmithKline Biologicals70
Active, not recruiting
Phase 1
A Phase I/II study to assess the safety and immunogenicity of recMAGE-A3+AS15 cancer immunotherapeutic given as adjuvant therapy, with or without standard adjuvant chemo(-radio)therapy, to patients with MAGE A3-positive Non-Small Cell Lung Cancer (stage IB, II or III) - MAGE3-AS15-NSC-001 (ADJ-Chemo)
EUCTR2006-004777-10-GBGlaxoSmithKline Biologicals72